Hamps Bio Limited IPO

About Hamps Bio Limited

Our Company was originally incorporated under the name Hamps Bio Private Limited under the provisions of the Companies Act, 1956 vide Certificate of Incorporation issued by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli on January 02, 2007. Subsequently, the status of the Company was changed to public limited and the name of our Company was changed to Hamps Bio Limited vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting of our Company held on June 08, 2023. The fresh certificate of incorporation consequent to conversion was issued on July 12, 2023 by the Registrar of Companies, Ahmedabad, Gujarat. The Corporate Identification Number of our Company is U24233GJ2007PLC049692.

India plays an important role in the global pharmaceuticals and vaccine industry. It is the largest provider of generic medicines globally. The country has a share of 20% in the global supply volume and contributes to around 60% of the global vaccines. India ranks third in the world in terms of volume and is the fourteenth largest in terms of value. Key segments of the Indian pharmaceutical industry are OTC medicines, Generics, APIs, Vaccines, Biosimilars, and Custom Research Manufacturing (CRM). The FMCG sector in India expanded due to consumer-driven growth and higher product prices, especially for essential goods. FMCG sector provides employment to around 3 million people accounting for approximately 5% of the total factory employment in India. FMCG sales in the country was expected to grow 7-9% by revenues in 2022-23. The key growth drivers for the sector include favourable Government initiatives & policies, a growing rural market and youth population, new branded products, and growth of e-commerce platforms. Resilience needs to be the key factor in the manufacturing process, daily operations, retail and logistic channels, consumer insights and communication that will help FMCG companies to withstand the test of time and create more value for consumers in the long run.

We are engaged in the ethical marketing and distribution of pharmaceutical formulation products (Pharma) across wide range of dosage including tablets, syrups, capsules, injectables, oil, gel and powder used as medicine and nutrition supplements as well as the manufacturing of freeze dried and frozen products (FDFP) such as fruits, vegetables, herbs and flowers. We are recognized in the pharmaceutical industry under our own brand name Hamps and in freeze-dried and frozen food segment through our own brand FzyEzy. We sell our products through more than 50 distributor's network as on October 31, 2024 and E-commerce platform, including Amazon.com, Amazon.ca, Amazon.eu, Flipkart, Jio Mart, Etc. We sell our pharma products primarily in 8 States and Union territories and our FDFP products primarily in 6 countries and 22 States and Union territories. As on the date of this Prospectus, we had a range of more than 180 different products sold across both the segments.

Strengths

Risk

Strategy